Brief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
03/09/2026 22:38
BRIEF-Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) Sept 3 (Reuters) - Spero Therapeutics, Inc. SPRO.O:
SPERO THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Source text: ID:nGNX8SF764
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)